Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic

Annals of Surgical Oncology

Volumn 13, Issue 5, 2006, Pages 685-691

  Klauber DeMore, Nancy ^a,b   Ollila, David W ^a,b   Moore, Dominic T ^b,c   Livasy, Chad ^a   Calvo, Benjamin F ^a,b   Hong, Jin Kim ^a,b   Dees, E Claire ^a,b   Sartor, Carolyn I ^a,b   Sawyer, Lynda R ^b   Graham II, Mark ^a,b   Carey, Lisa A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

Author keywords

Breast cancer; Lymph node metastasis; Micrometastasis; Neoadjuvant therapy; Tumor dormancy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROMETASTASIS; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 33645871608     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.03.010     Document Type: Article

References (15)

1. Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002; 236:295-302.
2. Carey LA, Metzger R, Dees EC, et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005; 97:1137-42.
3. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-85.
4. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998; 176:502-9.
5. Botti C, Vici P, Lopez M, Scinto AF, Cognetti F, Cavaliere R. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg 1995; 181:202-8.
6. Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002; 80:4-11.
7. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 1989; 124:21-5.
8. Carey CA, Dees EC, Dressler L, et al. Response to trastuzumab (Herceptin) given with paclitaxel (Taxol) immediately following 4 AC as initial therapy for breast cancer. Breast Cancer Res Treat 2002; 76(Suppl 1):4292.
9. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003; 83:803-19.
10. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet 1990; 335:1565-8.
11. Dowlatshahi K, Fan M, Bloom KJ, et al. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: a preliminary study. Cancer 1999; 86:990-6.
12. Newman LA, Pernick NL, Adsay V, et al. Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol 2003; 10:734-9.
13. Singh M, Capocelli KE, Marks JL, et al. Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer. Appl Immunohistochem Mol Morphol 2005; 13:147-56.
14. Klauber-Demore N, Van Zee KJ, Linkov I, Borgen PI, Gerald WL. Biological behavior of human breast cancer micrometastases. Clin Cancer Res 2001; 7:2434-9.
15. Ollila DW, Neuman HB, Sartor C, Carey LA, Klauber-Demore N. Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. Am J Surg 2005; 190:371-5.